Neuropsychiatry

Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group

Retrieved on: 
Wednesday, March 27, 2024
Depression, Neuropsychiatry, Partner, Psychiatry, ADHD, Mental, Partnership, LMHC, Transcranial magnetic stimulation, TMS, News, Acquisition, Brain, Region, Physician, Health, Dementia, Practitioner, Nursing

"We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.

Key Points: 
  • "We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.
  • Established in 2016, The Neuropsychiatry & TMS Group, led by Dr. Ahmed, has been dedicated to delivering exceptional mental health services.
  • With the support of Beacon, The Neuropsychiatry & TMS Group anticipates continued growth opportunities, including expanding its TMS services and recruiting additional physicians.
  • “I am pleased to announce our recent expansion into Florida, a natural progression for Beacon,” says Beacon Behavioral Partners CEO Sean Wendell.

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Tuesday, March 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Health, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • “The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, “We’re proud to be part of Gedeon Richter’s plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services.”

Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
Monday, March 18, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Week, Psychosis, Agitation, Commercialization, Medication, Psychiatry, Caregiver, Patient, Geriatric psychiatry, Overalls, MD, Lundbeck, NPI, CMAI, Neuropsychiatry, Safety, Poster, Behavioral neuroscience, Multimedia, Dementia, Annual general meeting, Food

One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.

Key Points: 
  • One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.
  • The NPI, which is administered through a structured caregiver interview, is comprised of 12 domains of neuropsychiatric symptoms including agitation/aggression, irritability/lability, and disinhibition.
  • The analysis demonstrated that REXULTI was associated with reductions in overall neuropsychiatric symptoms and in agitation symptoms (as captured by the NPI) compared with placebo over 12 weeks.
  • “The breadth of data presented at AAGP represents our continued commitment to understanding the full potential of REXULTI on agitation associated with dementia due to Alzheimer’s disease.”

MAPLIGHT THERAPEUTICS APPOINTS MARIA WALKER TO BOARD OF DIRECTORS

Retrieved on: 
Wednesday, April 3, 2024
KPMG, Entrepreneurship, Health, Patient, SAN, CNS, University, MD, Audit committee, MBA, Neuropsychiatry, Lightspeed Venture Partners, Therapy, Economics, Management

SAN FRANCISCO and BOSTON, April 3, 2024 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Maria Walker to its Board of Directors and audit committee. Ms. Walker brings more than 30 years of experience working with public and private companies across a variety of sectors, including healthcare, technology, venture capital and private equity.

Key Points: 
  • Walker brings 30+ years of investment, operational, and advisory experience
    SAN FRANCISCO and BOSTON, April 3, 2024 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Maria Walker to its Board of Directors and audit committee.
  • "We are thrilled to welcome Maria Walker to MapLight's board of directors," Christopher Kroeger, MD, MBA, MapLight CEO.
  • "We are thrilled to welcome Maria to MapLight's board," said Christopher Kroeger, M.D., MBA, MapLight's Chief Executive Officer and Co-Founder.
  • Ms. Walker also served as Audit Committee Chairman of ForgeRock and as Chief Financial Officer of Montes Archimedes Acquisition Corp.
    "This is an exciting time for MapLight and neuropsychiatry," said Ms. Walker.

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Neuropsychiatry, AbbVie, Post-traumatic stress disorder, Amygdala, CKD, Safety, World Health Organization, Therapy, CNS, Patient, Major depressive disorder, PTSD, DSM-IV codes, MDD, WHO, Partnership, Pharmaceutical industry

The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.

Key Points: 
  • The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.
  • A randomized, double-blind, active-controlled, multi-center Phase 3 trial to investigate the efficacy and safety of CKDB-501A in subjects with moderate-to-severe glabellar lines was completed in South Korea on November 20, 2023 (NCT05804656).
  • “This is clinically promising to see Healis’ lead protein, CKDB-501A, pass safety and efficacy in South Korea,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • Healis Therapeutics announced a strategic partnership with CKD Bio in 2024 to develop CKDB-501A for CNS indications.